⌕
Collegium Pharmaceutical · COLL · Nasdaq
Tenet 60 · Solid
Compare
$25.55+0.47%At closeTenet 60 · Solid
$25.55+0.12 (+0.47%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Collegium Pharmaceutical (COLL) Stock

Collegium Pharmaceutical (COLL) closed at $25.55 on Nov 17, 2026; its Tenet Score is 60 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

8 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$25.55
Nov 17, 2026
Market cap
$790.2M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
21.43 – 50.79
low → high · as of close, Nov 16, 2026
Tenet Score
60/100
Solid · 340 Healthcare peers

Industry: Drugs

Collegium Pharmaceutical Inc scores 60/100. Solid. Strongest on value and growth, financial health is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
60/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
87
Quality
62
Health
13
Growth
78

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityCHealthFGrowthBMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Withheld: our recalculation of this figure from its inputs did not match the reported value.
P/B
2.7×
Sep 30, 2026 balance sheet
P/S
1.0×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
13%
TTM through Sep 30, 2026
Operating margin
23.0%
fiscal 2025, before interest and tax
Net margin
4.7%
TTM through Sep 30, 2026
Current ratio
1.01
Sep 30, 2026 balance sheet
Net debt / EBITDA
2.6×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR,…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 108 US ETFs · top wrappers by weightSee all ETFs holding COLL →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Collegium Pharmaceutical in?

Collegium Pharmaceutical is in the Healthcare sector and the Drugs industry.

What is Collegium Pharmaceutical's Tenet Score?

Collegium Pharmaceutical's Tenet Score is 60 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.